Cowen reiterates Unilever stock rating on growth outlook By Investing.com

Unilever reported Q4 2025 revenue of $12.59B, missing the $15.95B consensus by ~21%, prompting a downgrade from Berenberg to Hold despite a higher PT of GBP58.40. TD Cowen reiterated a Buy with a GBP58.00 target, citing a PEG of 0.32, a Piotroski Score of 9, expected 2% volume growth in 2026 and strategic M&A (Liquid I.V., Nutrafol, Dr. Squatch, Minimalist) and management changes — creating mixed signals for the stock.

Analysis

Unilever’s ongoing shift toward higher-margin, small-format health & personal-care brands creates an asymmetric payoff: if management can scale a handful of bolt-on brands to mid-single-digit organic growth, the market will likely re-rate the group to peers over 12–24 months. That re-rating is not just multiple compression/expansion — it forces portfolio and index funds to adjust weights, creating mechanical buying pressure that can compound earnings-driven appreciation.

A less obvious effect is on the supply chain footprint. Shrinking big-format, cold-chain exposure lowers working-capital intensity and capital reinvestment needs, while a skew toward beauty/nutrition increases reliance on specialty contract manufacturers, niche packaging, and targeted e-commerce logistics. Those supplier categories have different margin and working-capital profiles, so margin improvement can be durable if the supplier base scales without pricing wars.

Primary risks are execution of integration and marketing-scale economics for recent bolt-ons, currency translation on global sales, and investor patience during sequential earnings misses. Near-term volatility will be driven by quarterly results and guidance revisions (days–months), while the fundamental test of the reflation thesis is 12–24 months of sustained volume/margin improvement.

Tactically, this is a re-rating trade, not a quick earnings bounce. The clearest way to isolate the multiple-normalization story is to own the company’s convexity (long equity or structured options) while hedging broad staples market exposure; event risks make capped-cost option structures and relative-value pair trades preferable to naked directional exposure.

Key Decisions for Investors

• Long UL (12–24 months): establish a position sized to 2–4% of equity risk budget. Use buy-and-hold equity or a 9–12 month call debit spread (ATM buy / +25–35% OTM sell) to cap premium. Target +30–40% total return if multiple converges; hard stop-loss at -15% from entry or cut if 2 sequential quarters of volume erosion.
• Pair trade — Long UL / Short PG (12 months): equal-dollar position to isolate valuation convergence vs incumbent peer. Rationale: if UL re-rates while PG stays stable, the spread should compress. Exit or trim if the relative underperformance of UL vs PG exceeds 200 basis points over a rolling 3-month window.
• Event volatility play (near term, 0–3 months): buy 1–3 month strangle/straddle around next earnings only if IV is < historical realized volatility; otherwise use a short-dated call spread to capture a post-earnings rebound while limiting downside premium decay. Keep exposure small (<1% of portfolio) due to binary risk.
• Tactical rotation (0–6 months): small overweight to cyclicals exposed to consumer rotation (e.g., select airlines DAL/ULCC) funded by slight underweight in industrials/automation if macro signals weakening capex. Size these as momentum trades with tight stops given macro sensitivity; view as liquidity-driven reallocation rather than fundamental conviction.